CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 500 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
[pSer2, pSer5, pSer7]-CTD TFA
<p>Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.</p>Formula:C98H138F3N21O39Purity:98%Color and Shape:SolidMolecular weight:2291.25PROTAC FLT3/CDKs degrader-1
<p>PROTACFLT3/CDKs degrader-1 (Compound C3) is an agent that degrades cyclin-dependent kinase (CDK2 with a DC50 of 18.73 nM) and FMS-like tyrosine kinase 3 (FLT3). It induces differentiation in HL-60 cells, achieving a 72.77% differentiation rate at 6.25 nM, and inhibits proliferation of acute myeloid leukemia (AML) cells, with an IC50 ranging from 2.9 to 37 nM. PROTACFLT3/CDKs degrader-1 demonstrates potential for improving the treatment of AML.</p>Formula:C40H42N12O5Molecular weight:770.34011dCeMM3
CAS:<p>dCeMM3 is a glue degrader that induces ubiquitination and degradation of cyclin K by promoting CDK12-cyclin K interaction with CRL4B ligase.</p>Formula:C14H11ClN4OSPurity:98.48% - 99.41%Color and Shape:SolidMolecular weight:318.78BSJ-03-204
CAS:<p>BSJ-03-204 is a selective Cdk4/6 degrader.</p>Formula:C43H48N10O8Color and Shape:SolidMolecular weight:832.9HTH-01-091 TFA
<p>HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.</p>Formula:C28H29Cl2F3N4O4Color and Shape:SolidMolecular weight:613.46CDK4/6-IN-5
CAS:<p>CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)</p>Formula:C22H28ClFN6O4SColor and Shape:SolidMolecular weight:527.01CPS2
CAS:<p>CPS2: potent, selective PROTAC CDK2 degrader. IC50=24nM, targets acute myeloid leukemia research.</p>Formula:C38H42N12O10S2Color and Shape:SolidMolecular weight:890.94CDK7-IN-7
CAS:<p>CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).</p>Formula:C20H20BrF3N6O2Color and Shape:SolidMolecular weight:513.319CDK12-IN-6
CAS:<p>CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).</p>Formula:C20H21F2N9Color and Shape:SolidMolecular weight:425.448JHD205
<p>JHD205 is an inhibitor of CDK4/6.</p>Formula:C32H40F2N8OColor and Shape:SolidMolecular weight:590.71IV-361
CAS:<p>IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1</p>Formula:C23H32FN5O2SiColor and Shape:SolidMolecular weight:457.625EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Formula:C49H32N12O2S2Purity:98%Color and Shape:SolidMolecular weight:884.99Multi-target kinase inhibitor 2
<p>Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 values</p>Purity:98%Color and Shape:Odour SolidCimpuciclib
CAS:<p>Cimpuciclib is a cyclin-dependent kinase(CDK) inhibitor and antineoplastic.</p>Formula:C30H35FN8OColor and Shape:SolidMolecular weight:542.663CDK6/9-IN-1
CAS:<p>CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).</p>Formula:C22H25ClN8OColor and Shape:SolidMolecular weight:452.95CDK4/6-IN-11
CAS:<p>CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.</p>Formula:C43H49N11O7Color and Shape:SolidMolecular weight:831.92PROTAC CDK9 degrader-7
CAS:<p>PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (</p>Formula:C43H50Cl2N8O9Color and Shape:SoildMolecular weight:893.81CDK-TCIP2
<p>DK-TCIP2 is an anticancer agent formed by linking the CDK9 inhibitor SNS-032 and the BCL6 inhibitor BI-3812. This compound exhibits anticancer activity both in vivo and in vitro, making it suitable for research in lymphoma.</p>Formula:C52H67ClN12O8S2Color and Shape:SolidMolecular weight:1087.75NecroIr2
<p>NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.</p>Formula:C46H30ClIrN6O2Color and Shape:SolidMolecular weight:926.44WAY-322243
CAS:<p>WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.</p>Formula:C18H18N2O2SPurity:99.88%Color and Shape:SoildMolecular weight:326.41
